nab-paclitaxel and pamrevlumab

This query refers to two distinct drugs: nab-paclitaxel and pamrevlumab. Nab-paclitaxel, also known as nanoparticle albumin-bound paclitaxel or protein-bound paclitaxel, is an injectable formulation of the chemotherapy drug paclitaxel. It utilizes albumin as a delivery vehicle to transport paclitaxel, which works by preventing the normal breakdown of microtubules during cell division, thereby killing cancer cells. Originally developed by VivoRx and Abraxis BioScience, its rights were subsequently acquired by Celgene and then Bristol Myers Squibb. It is approved for the treatment of metastatic breast cancer, non-small cell lung cancer (in combination with carboplatin), and metastatic adenocarcinoma of the pancreas (in combination with gemcitabine). Pamrevlumab (code name FG-3019) is a first-in-class, fully human monoclonal antibody developed by FibroGen. It was designed to inhibit the activity of connective tissue growth factor (CTGF), a protein central to fibrosis and proliferative disorders characterized by excessive scarring. Pamrevlumab was investigated for several fibrotic diseases and cancers, including idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). However, all pivotal Phase 3 clinical trials for these indications failed to meet their primary efficacy endpoints, leading to the termination of its development program by FibroGen.

Brand names

Abraxane

Other names

nanoparticle albumin-bound paclitaxelprotein-bound paclitaxelpaclitaxel NABAnti-CTGF antibody - FibroGenanti-connective tissue growth factor antibody